Karyopharm Therapeutics (KPTI) Income towards Parent Company (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Income towards Parent Company data on file, last reported at $131.4 million in Q4 2025.

• Quarterly Income towards Parent Company rose 187.72% year-over-year to $131.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $37.5 million (up 163143.48% YoY) and the FY2025 annual result came in at $37.5 million, up 163143.48% from the prior year.
• Income towards Parent Company climbed to $131.4 million in Q4 2025, from -$33.1 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $131.4 million in Q4 2025 to a low of -$57.4 million in Q1 2021.
• A 5-year average of -$12.6 million and a median of -$34.3 million in 2023 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2023 — Income towards Parent Company jumped 356.63% — and 2025, when it slumped 256.57%.
• Tracing KPTI's Income towards Parent Company over 5 years: stood at $38.7 million in 2021, then plunged by 201.83% to -$39.4 million in 2022, then jumped by 356.63% to $101.2 million in 2023, then sank by 54.87% to $45.7 million in 2024, then soared by 187.72% to $131.4 million in 2025.
• The last three Income towards Parent Company figures came in at $131.4 million (Q4 2025), -$33.1 million (Q3 2025), and -$37.3 million (Q2 2025), per Business Quant data.